APP and glycogen storage disease VI: The binding to pathogenic forms of Abeta including truncatedpGlu-Abeta3–42 species have been speculated to be clinically important inAlzheimer’s disease.5 This notion is now receiving clinical validation as a proof ofconcept study involving passive immunization with a mAb, Donanemab (LY3002813),specific for pyroglutamate Abeta, has demonstrated encouraging clinical results in arecently published Phase 2 clinical study.10